Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) Stock Price Down 4.3% – Here’s Why

Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) shares dropped 4.3% during mid-day trading on Monday . The stock traded as low as $28.71 and last traded at $28.71. Approximately 226 shares changed hands during mid-day trading, an increase of 3% from the average daily volume of 220 shares. The stock had previously closed at $29.99.

Analyst Ratings Changes

Separately, Barclays raised Swedish Orphan Biovitrum AB (publ) to a “strong-buy” rating in a research note on Wednesday, January 8th.

Swedish Orphan Biovitrum AB (publ) Stock Performance

The company has a quick ratio of 0.62, a current ratio of 0.91 and a debt-to-equity ratio of 0.31. The company has a 50 day simple moving average of $29.55 and a 200-day simple moving average of $29.71. The stock has a market capitalization of $10.22 billion, a price-to-earnings ratio of 27.61 and a beta of 0.62.

About Swedish Orphan Biovitrum AB (publ)

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still’s disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection.